A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Participants With Chronic Heart Failure With Reduced Ejection Fraction (ASTRAAS-HF)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04836182 |
Recruitment Status :
Completed
First Posted : April 8, 2021
Last Update Posted : September 11, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Chronic Heart Failure With Reduced Ejection Fraction | Drug: IONIS-AGT-LRx Drug: Placebo | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 72 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | A Double-Blind, Placebo-Controlled, Randomized, Multicenter, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of IONIS-AGT-LRx, an Antisense Inhibitor of Angiotensinogen Production, Administered Subcutaneously Over 12 Weeks in Patients With Chronic Heart Failure With Reduced Ejection Fraction |
Actual Study Start Date : | June 8, 2021 |
Actual Primary Completion Date : | October 19, 2022 |
Actual Study Completion Date : | January 11, 2023 |
Arm | Intervention/treatment |
---|---|
Experimental: IONIS-AGT-LRx
IONIS-AGT-LRX by subcutaneous injection once-weekly
|
Drug: IONIS-AGT-LRx
Multiple doses of IONIS-AGT-LRx will be administered by SC injection.
Other Name: ISIS 757456 |
Placebo Comparator: Placebo
Matching placebo by subcutaneous injection once-weekly
|
Drug: Placebo
IONIS-AGT-LRx-matching placebo will be administered by SC injection. |
- Percent Change in Plasma AGT Concentration From Baseline to Study Day 85 [ Time Frame: Baseline to Day 85 ]
- Absolute Level of Plasma AGT [ Time Frame: Baseline to Day 169 ]
- Change in Plasma AGT From Baseline to Each Scheduled, Post-Baseline Visit [ Time Frame: Baseline to Day 169 ]
- Percent Change in Plasma AGT From Baseline to Each Scheduled, Post-Baseline Visit [ Time Frame: Baseline to Day 169 ]
- Absolute Level of NT-proBNP [ Time Frame: Baseline to Day 169 ]
- Change in NT-proBNP From Baseline to Each Scheduled, Post-Baseline Visit [ Time Frame: Baseline to Day 169 ]
- Percent Change from Baseline in NT-proBNP to Each Scheduled, Post-Baseline Visit [ Time Frame: Baseline to Day 169 ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 80 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Females must be non-pregnant and non-lactating and of non- childbearing potential.
- Males must be surgically sterile or, abstinent or, if engaged in sexual relations with a woman of child-bearing potential (WOCBP), she must be willing to use a highly effective contraceptive method
- Screening NT-proBNP ≥ 600 picograms per milliliter (pg/mL) and less than (<) 8500 pg/mL
- Established diagnosis of heart failure (HF) with reduced systolic function for at least 6 months prior to the screening visit (left ventricular ejection fraction, [LVEF] ≤ 40%
- New York Heart Association class I-III
Participants should receive background standard of care for HFrEF. Therapy should have been individually optimized and stable for ≥ 4 weeks before randomization and include:
- An angiotensin-converting-enzyme inhibitor (ACEi), or angiotensin II receptor blockers (ARBs) or sacubitril/valsartan (mandatory)
- A beta-blocker (unless contraindicated or not tolerated)
- A mineralocorticoid receptor antagonist (MRA, unless contraindicated or not tolerated)
Exclusion Criteria:
- HF due to restrictive cardiomyopathy, active myocarditis, chemotherapy, hypertrophic cardiomyopathy, primary cardiac valve disease, non-compaction cardiomyopathy, or takotsubo cardiomyopathy.
- Acute decompensated HF requiring intravenous (IV) diuretics, IV inotropes or IV vasodilators with discharge date within 30 days of screening or acute mechanical support (e.g., intra-aortic balloon pump, endotracheal intubation, mechanical ventilation, or any ventricular assist device) with discharge date within 90 days of screening.
- Symptomatic hypotension or systolic blood pressure (SBP) ≤ 90 millimeters of mercury (mmHg) at screening.
- Uncontrolled hypertension (HTN) (SBP > 160 mmHg or diastolic blood pressure (BP) > 100 mmHg) prior to screening.
- Heart transplant, and/or Left Ventricular Assist Device (LVAD) prior to screening or anticipated heart transplant or LVAD during the study.
- Implantation of a cardiac resynchronization therapy device (CRT) within 3 months prior screening or intent to implant a CRT within 3 months after screening.
- Acute coronary syndrome, unstable angina, stroke, transient ischemic attack (TIA), coronary revascularization, cardiac device implantation, cardiac valve repair, carotid or other major surgery within 3 months of screening.
- Coronary, valve or carotid artery disease likely to require surgical or percutaneous intervention within the 3 months after screening.
-
Severe pulmonary disease with any of the following:
- Requirement of continuous (home) oxygen or
- Known diagnosis of severe chronic obstructive pulmonary disease (as defined by the American Thoracic Society/European Respiratory Society) or severe restrictive lung disease, in the opinion of the investigator.
-
Screening laboratory results as follows, or any other clinically significant abnormalities in screening laboratory values that would render a participant unsuitable for inclusion in the opinion of the investigator.
- Alanine aminotransferase/aspartate aminotransferase (ALT/AST) > 2.0 × upper limit of normal (ULN).
- Total bilirubin ≥ 1.5 × ULN (participants with total bilirubin ≥ 1.5 × ULN may be allowed on study if indirect bilirubin only is elevated, ALT/AST is not greater than the ULN, and known to have Gilbert's disease).
- Platelets < 100,000/millimeter^3 (mm^3).
- Urine protein creatinine ratio (UPCR) ≥ 500 milligrams per gram (mg/g).
- Hemoglobin A1c (HbA1c) > 9.5% or uncontrolled diabetes per investigator judgement.
- Estimated glomerular filtration rate (eGFR) < 30 milliliters/ minute /1.73 m^2 (mL/min/1.73 meter^2) at screening.
- Abnormal thyroid function tests with clinical significance per investigator judgement.
- Serum potassium > 5.1 millimoles per liter (mmol/L) at screening.
- Requirement of treatment with both ACEi and ARBs.
- Previous history of intolerance to ACEi or ARBs or history of hyperkalemia.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04836182
Responsible Party: | Ionis Pharmaceuticals, Inc. |
ClinicalTrials.gov Identifier: | NCT04836182 |
Other Study ID Numbers: |
ISIS 757456-CS5 2020-005878-10 ( EudraCT Number ) |
First Posted: | April 8, 2021 Key Record Dates |
Last Update Posted: | September 11, 2023 |
Last Verified: | September 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Heart Failure AGT NT-proBNP |
Heart Failure Heart Diseases Cardiovascular Diseases |